1,854 Shares in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Purchased by Virtus Fund Advisers LLC

Virtus Fund Advisers LLC acquired a new position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 1,854 shares of the specialty pharmaceutical company’s stock, valued at approximately $72,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Pacer Advisors Inc. increased its stake in shares of Collegium Pharmaceutical by 31.8% in the second quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after acquiring an additional 821,541 shares during the last quarter. Rubric Capital Management LP grew its stake in Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock valued at $75,139,000 after purchasing an additional 499,473 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Collegium Pharmaceutical by 411.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 362,137 shares of the specialty pharmaceutical company’s stock worth $11,661,000 after purchasing an additional 291,286 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Collegium Pharmaceutical by 43.6% during the 3rd quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock valued at $27,461,000 after buying an additional 215,874 shares during the last quarter. Finally, Emerald Advisers LLC grew its stake in shares of Collegium Pharmaceutical by 27.2% in the 3rd quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after buying an additional 177,129 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $29.87 on Friday. The firm has a market capitalization of $963.31 million, a PE ratio of 12.88 and a beta of 0.80. Collegium Pharmaceutical, Inc. has a 1 year low of $26.09 and a 1 year high of $42.29. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The firm’s fifty day simple moving average is $34.37 and its 200 day simple moving average is $34.54.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares in the company, valued at approximately $1,970,741.92. This trade represents a 15.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.98% of the company’s stock.

Analysts Set New Price Targets

COLL has been the topic of several recent research reports. StockNews.com lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 23rd. HC Wainwright lifted their price objective on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, September 5th. Piper Sandler reiterated a “neutral” rating and issued a $37.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Truist Financial raised their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average price target of $42.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.